InjectionClinical Overview
Cefepime and Tazobactam is an advanced parenteral combination of a fourth-generation cephalosporin and a beta-lactamase inhibitor. Cefepime penetrates the outer bacterial membrane rapidly and possesses low affinity for AmpC beta-lactamases, while tazobactam neutralizes extended-spectrum beta-lactamases (ESBLs). Indicated for severe nosocomial pneumonia, febrile neutropenia, complicated intra-abdominal infections, and multi-drug resistant urinary sepsis.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Administered intravenously by slow IV injection over 3-5 minutes or IV infusion over 30 minutes by certified clinical professionals after reconstitution with sterile diluent.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Phlebitis, diarrhea, nausea, rash, headache, fever. Rare/Severe: Neurotoxicity (encephalopathy, aphasia, myoclonus, seizures in renal patients), anaphylaxis, and Clostridioides difficile colitis.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Requires careful dose titration in patients with renal clearance < 60 mL/min to prevent neurotoxic encephalopathy. Contraindicated in cephalosporin or beta-lactamase inhibitor allergy.
Schedule H1 (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Ceftriaxone 1g + Tazobactam 125mg Injection
Ceftriaxone Sodium and Tazobactam Sodium combines an extended-spectrum third-generation cephalosporin with the potent beta-lactamase inhibitor tazobactam. Tazobactam prevents ceftriaxone hydrolysis by plasmid- and chromosome-mediated beta-lactamases, restoring full bactericidal activity. Indicated for severe polymicrobial infections, meningitis, sepsis, complicated skin/soft tissue infections, and hospital-acquired lower respiratory infections.
Ceftriaxone 250mg + Tazobactam 31.25mg Injection
Ceftriaxone Sodium and Tazobactam Sodium combines an extended-spectrum third-generation cephalosporin with the potent beta-lactamase inhibitor tazobactam. Tazobactam prevents ceftriaxone hydrolysis by plasmid- and chromosome-mediated beta-lactamases, restoring full bactericidal activity. Indicated for severe polymicrobial infections, meningitis, sepsis, complicated skin/soft tissue infections, and hospital-acquired lower respiratory infections.
Cefepime 250 Mg Inection
Cefepime is a fourth-generation parenteral cephalosporin bactericidal antibiotic. Its zwitterionic structure allows rapid penetration through Gram-negative bacterial outer membrane porins, providing broad coverage against both Gram-positive organisms (MSSA, streptococci) and Gram-negative bacilli, including Pseudomonas aeruginosa and AmpC-producing Enterobacteriaceae. Indicated for empirical monotherapy in febrile neutropenia, severe hospital-acquired pneumonia, complicated intra-abdominal infections, and complicated pyelonephritis.